Sabicard 97 mg+103 mg (Tablet)
Unit Price: ৳ 120.00 (1 x 10: ৳ 1,200.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Aristopharma ltd |
| Also available as |
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older
- Administered in conjunction with other heart failure therapies
- Use in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB
Pharmacology
- Contains neprilysin inhibitor, sacubitril, and angiotensin receptor blocker, valsartan
- Inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657
- Blocks the angiotensin II type-1 (AT1) receptor via valsartan
- Effects attributed to increased levels of peptides degraded by neprilysin and simultaneous inhibition of the effects of angiotensin II by valsartan
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Target maintenance dose for adult heart failure: 97/103 mg orally twice daily
- Recommended dose for pediatric patients aged one year and older
- Dose adjustment for renal and hepatic impairment
Interaction
- Should not be used with an ACEi, aliskiren in patients with diabetes
- Use with an ARB should be avoided
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Increased risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required for mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum creatinine and down-titrate in patients with decreased renal function
- Monitor serum potassium periodically and treat appropriately
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No starting dose adjustment needed for mild or moderate renal impairment
- Starting dose adjustment recommended for patients with severe renal impairment or moderate hepatic impairment
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available
- Hypotension is the most likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children